1

CURRICULUM VITAE

PROFESSOR ROGER D. JAMES, FRCP, FRCR

MAY 2011

2

- CURRICULUM VITAE -

Name: Roger David James

Telephone: 07767 611608

Year of Birth: 1946

Marital Status: Married / 3 children

QUALIFICATIONS

MB BCh (Cantab) 1971

MRCP (UK) 1977

FRCR 1979 FRCP 2002

MEDICO-LEGAL DETAILS GMC Principal List Registration Number 1461972 Medical Defence Union Membership and Professional Indemnity Number 092682A

CURRENT POSITION

Retired (2009) Consultant in Oncology and Radiotherapy (Maidstone and Tunbridge Wells NHS Trust)

NATIONAL AWARDS

Platinum (A+) National Award 2007

PREVIOUS POSITION

Clinical Director and Divisional Director, Cancer Services 1999-2006 Deputy Medical Director, Maidstone and Tunbridge Wells NHS Trust 2006-8 Medical Director, Kent and Medway Cancer Network 1999-2008

Consultant in Oncology and Radiotherapy 1979 - 1999 The Christie Hospital NHS Trust Wilmslow Road

3

Withington Manchester M20 4BX

SECONDARY EDUCATION Wolverhampton Grammar School 1958 - 1964

TRAINING POSTS HELD Medical School Trinity College, Cambridge 1964 - 1967

St Bartholomew's Hospital, London 1967 - 1970

House Officer 1970 - 1971 Southend General Hospital

Medical Officer 1971 - 1974 Overseas Development Administration ZAMBIA

Senior House Officer 1974 - 1975 Southend General Hospital

Registrar 1975 - 1977 The Middlesex Hospital, London

Senior Registrar 1977 - 1979 Mount Vernon Hospital, London

Berkeley Scholar 1979 Massachusetts General Hospital USA

4

MANAGERIAL AND ADMINISTRATIVE DUTIES

1.Locality

Christie Hospital NHS Trust (1979 - 1999)

Chairman - Hospital Research Committee (Quarterly) 1992 - 1996

Chairman - Clinical Research Laboratory Management 1996 - 1999 Committee (Quarterly)

Member - Lymphoma Group (Weekly) 1979 - 1999

Chairman - BMA Local Negotiating Committee (Quarterly) 1991 - 1999

Chairman - Gastrointestinal Group (Monthly) 1996 - 1999

Co-Ordinator - Clinical Oncology Research Group (Monthly) 1996 - 1999 Maidstone and Tunbridge Wells NHS Trust (1999-present) Deputy Medical Director ` 2007 - 9 Divisional Medical Director 2007 - 8 Clinical Director - Joint Oncology Centre (Maidstone-Canterburty) 1999 - 2007 Associate Medical Director (Cancer Services) 1999 -2005 Clinical Director, Cancer Clinical Directorate` 2005 - 2007 Member - Hospital Trust Management Committee 1999 - 2008 Member - Hospital Trust Medical Board 2000 - 2008 Chairman - Joint Oncology Consultant's Committee 1999 - 2007 Chairman - Trust Quality Assurance (Radiotherapy) Board 2001-2007 Chairman - Trust Higher Awards (Clinical Excellence) Committee 2003 - 2008

Member - Cancer Management Board, Kent Cancer Centre 1999 - 2001 Member - Trust Research and Development Committee 2001 - 2008 Member - Trust Discretionary Points Committee 1999 - 2008

2.Health Authority

Kent and Medway Cancer Network

5

Chair - Clinical Advisory Team 2001 – 2007 Network Chemotherapy Group 2004 - 2007 Clinical Lead - Kent Cancer Collaborative 1999 - 2003 Chair - Canterbury Oncology Contingency Planning Group 2001 - 2003 Chair - Network Informatics Group 2002 - 2007 Chair - Commissioning and Implementation Group 2002 -2003 Member - Chief Executives Committee 2001 - 2008 Member - Research and Education Committee 2001 - 2006 Member - Drugs & Therapeutics Committee 1999 - 2007 Evidence to Public Consultation, East Kent on Cancer Services 2002 Evidence to Kent County Council Overview & Scrutiny Committee 2002, 2003 Kent Clinical Co-ordinator - National Review of Hodkins' Disease/Breast Cancer 2003

6

3. Regional

3.1. North West Regional Office Medico-Political

Vice Chairman - North Western Regional Consultants & Specialists 1995 - 1999 Committee.

Chairman - North Western Regional L.N.C. Forum 1991 - 1999

Member - North West Local Medical Workforce Advisory Group 1997 - 1999

Regional North West Representative - Royal College of Radiologists 1996 - 1999 (Clinical Oncology) Research

Clinical Co-ordinator - Greater Manchester Home Infusion Project 1996 - 1999

NHS Administrative Member - NW Regional Office, 1996 - 1999

Calman Cancer Implementation Group 3.2. South East Regional Office Chair - SE Regional Clinical Directors, Radiotherapy 1999-2001 Clinical Lead - SE Regional Office Cancer Collaborative 2001 - 2002 Member - SE Regional Office Cancer Task Force 2000 -2001 Member - SE Regional Office Peer Review Group 2000 - 2001 Member - SE Regional Office (later Zonal) Steering Group 2002-2003

for Pancreatic Cancer Member - SE Regional Office Chemotherapy Review 2002 Member - NPfIT Kent & Medway Clinical Advisory Group 2001-6 Member - NPfIT Joint Kent & Medway, Surrey & Sussex 2006 -2008 Clinical Advisory Group Member - Clinical Reference Group, Kent & Medway Acute Services Review 2006 -7

7

4. National

4.1 Medico-Political Member - BMA Central Consultant's Specialists Committee 1997 - 1999 (Quarterly) 4.2 NHS Administrative Secretary - National Committee, Cancer Network Clinical Directors 2003 -2007 Governance Lead - National Committee, Cancer Network Clinical Directors 2007 Member - Cancer Action Team Clinical Advisory Committee 2003 - National clinical lead - Modernisation Agency, Cancer Chemotherapy 2003 - NHS Executive - COG Expert Advisory Group, Colorectal Cancer, 1996 - 1997 Upper GI Cancers Member - Thames Cancer Registry Clinical Advisory Group 1999 - 2008 Peer Reviewer - National Instutute of Clinical Excellence 2002 A Review of the Evidence for the Clinical and Cost- Effectiveness of Capecitabine and Tegafur with Uracil for The treatment of Metastatic Colorectal Cancer Expert Advisor - National Instutute of Clinical Excellence 2004 Supportive and Palliative Care Guidance Evidence to National Independent Review Panel on Kent Cancer Services 2003 Member, West Kent Strategic Services Review 2006 Formal External Reviews

Surrey, West Sussex & Hampshire 2002 Cancer Network Lancashire and South Cumbria Cancer Network Review of Population-based

Reorganisation of Surgery for Upper GI Cancers 2003 Central South Coast Cancer Network External Clinical Pancreatic Review Jan. 2004 Surrey, West Sussexs & Hampshire Feb. 2004 Cancer Network: Upper Gastrointestinal Cancers Presentations to Kent County Council Overview & Scrutiny Committee 2002, 2003 4.3 Collegiate Member - L.H. Gray Trust (Quarterly) 1987 - 92 Member - NW Regional Representatives Committee, 1996 - 9

8

Royal College of Radiologists Member - Examining Board, Royal College of 1988 - 1993 Radiologists (Quarterly)

Member - Clinical Oncology Information Network on 1997 - 2001 Colorectal Cancer, Royal College of Radiologists Member - Council of Association of Coloproctology of GB. & Ireland (Quarterly) 1997 - 2000 Member - Research committee, Association of Coloproctology of GB. & Ireland (Quarterly) 1999 - 2003

Member - Clinical Oncology Audit Sub-Committee Royal College of Radiologists 1997 - 2005 Member - Heads of Service Committee, 1999 -3

Royal College of Radiologists Member - RCR Clinical Leads Committee 2003 -6

Chair - JCCO Working Party 'Bed needs for Oncology' 2003 -4

9

RESEARCH

Member - MRC Colorectal Cancer Working Party 1979 - 1997 Member - UKCCCR (now NCRN) Colorectal Cancer Sub-Committee 1997 – 2007 Member - UKCCCR Anal Cancer SubCommittee 2007 - 8 Chairman - UKCCR National Colorectal Trial (AXIS) 1989 - 98 (Twice yearly) Member - UKCCR 'ACT I' Anal Cancer Trial (Quarterly) 1987 - 1999 National Principle InvestigatorUKCCCR/NCRN 'ACT II' Anal Cancer Trial 1999 - Joint Clinical - Medical Research Council - 'CR08' Focus Trial 1998 - 2000 Coordinator (QA)

Member - UKCCR Quasar 1 Trial Group (Quarterly) 1987 - 1992 Member - NCRN Quasar 2 Trial management Group 1999 - 2001 Principle Investigator, Kent - NCRN Quasar Trial 2004 - 2006 Member - Steering Group MRC 'CRO7' Trial 1998 - 1999

Member - Association of Coloproctology 1999 - 2001 Clinical Research Group Clinical Co-ordinator - CDSS General Practice CD-ROM Data Set 1997 -8 Member, Research & Education Committee, KIMHS, University of Kent 1999- 2003 Chair, Trial Steering Committee, FACS Trial 2004 – 8 Clinical Lead, ‘Best Research for Best Health’ Kent Bid 2007-8 Chair, ACT 2 Steering Group 2000 - 7 Miscellaneous Medical Advisor - 'Beating Bowel Cancer' 2002 - 6

10

Teaching - Invited Speaker at Plenary Sessions of UK National Meetings Association of Coloproctology M62 Teaching Course, Leeds Feb 1998

UK Key Advances in Clinical Practice (BMA), London June 1998 Annual Meeting Association of Coloproctology, Jersey June 1998 Annual Meeting: Coloproctology Specialist Nurses, Cumbria June 1998

Joint Meeting of British Oncological Association July 1999 Association of Cancer Physicians, Royal College of Radiologists International Colorectal Cancer Symposium, Nottingham October 1999

New Perspectives in Colorectal Cancer Treatment, London November 1999 All Party Group on Cancer - House of Commons Clinical Advisory Group November 1999 All Party Group on Cancer - House of Commons Clinical Advisory Group July 2000 The Clinical Audit Association , Annual Meeting, Brighton June 2000 The Four Counties Cancer Network Conference, Aylesbury September 2000 The Central South Coast Cancer Network Conference, Southampton October 2000 Cancer Care in the Third Millenium, University of Canterbury October 2000 The Cambridge Cancer Network Launch Meeting November 2000 Managed Care Networks, Royal College of Physicians, London December 2000 The North Trent Cancer Network, Palliative Care Group, Doncaster April 2001 Cancer Services and the NHS Plan, London September 2001 The Building Blocks of Palliative Care Networks, London October, 2001 Clinical Networks, London October, 2001 Key Advances in the Management of Colorectal Cancer, London November, 2001 Key Advances in the Management of Non-Hodgkins' Lymphoma, London November, 2001 Delivery of Radiotherapy & Chemotherapy in Clinical Oncology, London November, 2001 Inaugural Meeting of Association of Community Cancer Care, Birmingham, December, 2001 Managed Clinical Networks, London February, 2002 The Clinical Leadership of Data Management in Cancer Networks, London, June 2002 Development of clinical networks for supportive/palliative care, London, June 2002 Delivering Effective Ovarian Cancer Services, London July 2002

11

The NHS Cancer Plan, Reality or Rhetoric? London October 2002 Safety, Quality Control and Clinical Governance in Radiotherapy, London November 2002 Inaugural Meeting of ACP Young Consultant's Group, Birmingham March 2003 Colorectal Cancer Update, RC of Nursing, London October 2003 Combined Chemotherapy and Radiotherapy in GI Tumours, London October 2003 Colorectal Cancer - A Clinical Update, London October 2003 NHS Modernisation Agency - Chemotherapy Workshop, Leeds November 2003 Key Advances in Upper GI Malignancy, London November 2003 National Chemotherapy Workshop, London December 2003 Cancer Development Workshop, Redditch February 2004 Health & Social Care Quality Centre: Cancer Services, London March 2004 Royal College of Radiologists Meeting: Chemotherapy Workshop, London March 2004 National Chemotherapy Workshop, Leeds September 2004 Brithish Oncology Pharmacists Association, Birmingham October 2004 Association of Cancer Physicians, Birmingham April 2005 Chemotherapy Advisory Group National Meeting, London June 2005 Keele University NHS Leadership Course June 2005 Cancer Network Development Programme, London October 2005 Royal College of Radiologists Meeting: Postgraduate Teaching February 2006 HC2006 IT Conference, Harrogate March 2006 National Lung Cancer Conference, Birmingham June 2006 Oncology in Primary Care, London June 2006 New Cancer Drugs and Therapies, Essex October 2006 Chemoradiotherapy in Anal Cancer, London October 2007 Network Diversification in Chemotherapy, Hull April, 2008 Network Chemotherapy Stakeholders, Manchester May, 2008 NCRI Conference, Birmingham October 2008 ACT II, ARISTOTLE Investigator meeting, London May 2009 CPORT: Optimising Chemotherapy Services for Patient Benefit, London June 2009

12

World Class Chemotherapy and NCAG, Birmingham July 2009 Lower GI Cancer, London March 2010 Oral Chemotherapy in Cancer, Glasgow March 2010 Central South Coast Cancer Network, Southampton April 2010 Cancer Strategy Business Case, Worcester May 2010 Developing an NHS Business Case, Cheshire Sept 2010 Developing an NHS Business Case, Glasgow Oct 2010 Equity and Excellence. Working with the new NHS, London April 2011 INTERNATIONAL

Principal Supervisor - DHSS, UK/USSR Health Care Agreement 1988 - 93 Tumour Cell Biology, Clinical Aspects of Radiotherapy Member - Cochrane Cancer Network (Colorectal) 1997 - 2001 Clinical Co-ordinator - USA Federal Drug Administration Inspection Visit Manchester October 1998 Clinical Lead - Kent/Sussex/Normandy Inter-reg Project 2003 -7 Chairman - EU Chemotherapy Network 2004 -6 Clinical lead - 'Salick' Project 2003 -6 Invited Speaker at Plenary Sessions of International Meetings Swedish Coloproctology Group, Stockholm 1995 American Society of Coloproctology, Chicago 1994

Lyons Cancer Group Lyons1996

Zagreb Cancer Group Zagreb 1997

IV Spanish Conference on Controversies in Oncology Murcia, 1998 Annual Meeting Japanese Society of Medical Oncology Furvoka 1998

European Society of Medical Oncology Athens 1998

Argentina Society of Medical Oncology l Buenos Aires1998

Turkish National Congress on Oncology Antalya - May 1999

European Congress of Clinical Oncology Vienna - Sept 1999

13

VI th National Bulgarian Congress in Oncology Sofia - Nov 1999 Italian Society of Coloproctology Naples - June 2000 Peruvian Society of Oncology Lima - July 2001 Croatian Cancer Conference Dubrovnik -Jun 2002 Polish Cancer Conference Warsaw May 2007 East Germany Cancer Conference Leipzig October 2007 Hungarian Cancer Conference, Budapest Nov 2007 European Society of Medical Oncology, Stockholm Sept 2008 Polish Cancer Conference, Warsaw Nov 2008 American Society of Clinical Oncology Annual Meeting, Florida June 2009 South East of Ireland Oncology Meeting, Waterford, Ireland Sept 2009 Joint ECCO, ESMO Meeting, Berlin Sept 2009 International chemotherapy consensus meeting, London June 2010 Developing the Oral Chemotherapy Service, Ravenna Sept 2010

14

MEMBERSHIP OF PROFESSIONAL BODIES Royal College of Physicians 1974 - Royal College of Radiologists 1976 - Royal Society of Medicine 1973 - British Institute of Radiology 1974 - 95 Association of Coloproctology (Great Britain and Ireland) 1984 - 95 European Association of Coloproctology 1999 - 95 British Association of Medical Managers 2000 - 2009 American Society of Clinical Oncology 2001 - 2009 European Society of Medical Oncology 2001- 2009 Healthcare Financial Management Association 2009- UNIVERSITY ADMINISTRATIVE WORK

Final year research project supervisor - University of Manchester Medical School:

1994 Dr M Stamp - Psychological impact of chemotherapy of colorectal cancer.

1995 Dr D Lewis Is a diary card a suitable tool for assessing quality of life in colorectal cancer patients ?

1996 Dr J Moore The psychological impact and use of alternative therapies for colorectal cancer patients receiving adjuvant chemotherapy.

1997 Dr D Fairhurst Expression of P-27 in colorectal cancer.

1997 Dr M Odale Do primary health care characteristics affect mode of admission and prevalence of self medication in patients with colorectal cancer?

1998 Dr R Thompson Expression of thymidilate synthase in colorectal cancer specimens.

1999 Dr C Hayman Emergency admission for surgery predicts disease progression

RESEARCH GRANTS HELD

*New prognostic variables determining the response of colorectal adenocarcinomas to surgery and radiotherapy. Value £120,000 over 3 years (1991-94)

*Can the administration of growth factors enhance the recovery of epithelial and stromal tissues following irradiation? Value £105,00 over 2 years (1993-95)

*New prognostic variables governing response to of colorectal adenocarcinomas to surgery and radiotherapy. Value £42,197 over 2 years (1994-96)

15

* Large bowel mutational susceptibility and expression of O6

-alkylguanine DNA alkyltransferase Value £70,137 over 2 years (1998-2000) * Funded by Endowment Fund, Christie Hospital.

SUPERVISION OF TRAINEE SURGEONS FOR THE DEGREE OF M.D.

1993-95 Dr M Wilson Measurement of proliferation in colorectal cancer.

1995-96 Dr P Marsh Immunoassay of 5-T4 and p-53 in colorectal cancer.

1996-97 Dr L Jones Apoptosis in colorectal cancer

1997-98 Dr R West Mismatch repair

I organised two Focus Meetings on gastro-intestinal cancer for Greater Manchester during 1997 and supervised M.D. projects in collaboration with Miss S O'Dwyer and Dr E Anderson, previously with Professor P Schofield. From 1990 -99 I was largely responsible for ensuring the continuation of colorectal cancer laboratory research on-site. I have also jointly supervised M.D. projects with Professor Hendry in Radiobiology. The latest project concerns growth factors, but in the 1980's we worked for 5 years on hyperthermic projects. This work also involved Endowment funded research and the Regional Department of Physics. In the early 1990's with Dr P M Wilkinson I was jointly responsible for a research project on Erythiopoietin in Ovarian Cancer. Dr R Welch worked in Dr N Testa's laboratory on assay development and this research continued with a current M.D. project.

EDITORIAL/REFEREEING

Member - Editorial Board, International Journal of Coloproctology 1996-9 Member - Editorial Board, 'Colonews' 1995 - 2000

Internal Assessor - University of Manchester 1985-99

Referee - British Journal of Cancer 1980- International Journal of Cancer Journal of Radiation Biology Clinical Oncology

16

PUBLICATIONS Italicised references are citable in peer-reviewed journals

1. James RD (1979) When should radiotherapy be given for rectal cancer? Dis Col Rectum, 22: (7), 455-8.

2. James RD & Davey AT (1979) Mitotic index in carcinoma of the lung (letter). Lancet Oct 20: 2: (8147), 852.

3. James RD (1980) Radiotherapy in the management of gastrointestinal carcinoma: a review. J Roy Soc Med, 73: (9), 659-653.

4. James RD & Bullock N. (1981) Who should be given radiotherapy for carcinoma of the rectum? In: Gerard A (ed). Progress and perspectives in the treatment of gastrointestinal tumours. New York, Pergamon Press, p 105.

5. James RD, Johnson RD, Eddleston B, Zhueg GL & Jones JM (1983) Prognostic factors in locally recurrent rectal carcinoma treated by radiotherapy. Br J Surg, 70: (8), 469-472.

6. James RD & Schofield PF (1983) Alternatives in the management of rectal and anal cancer. In: Irving M and Beart RQ (eds). Gastro-enterological surgery, London, Butterworths, p 198.

7. Anderson H, Deakin DP, Wagstaff J, Jones JM, Todd IDH, Wilkinson PM, James RD, Steward WP, Blackledge G, Scarffe JH & Crowther D (1984) A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PSIA-IIB: A report from the Manchester Lymphoma Group. Br J Cancer, 49: 695-702.

8. Canney PA, Moore M, Wilkinson PM & James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer, 50: (6), 765-769.

9. James RD & Pye D (1984) Patient intolerance to local hyperthermia. Hyperthermia Oncology 1984, V 1, pp 833-6, (eds) J Overgaard,Taylor and Francis, London, New York.

10. Zheng G, Johnson RJ, Eddleston B, James RD & Schofield PF. (1984) Computed tomographic scanning in rectal carcinoma. J R Soc. Med. 77: (11): 915-920.

11. Canney PA, Moore M, Wilkinson PM & James RD (1985) CA 19-9 as a marker for ovarian cancer alone and in comparison with CA 125. Br J Cancer, 52: 131-133.

12. James RD (1985) Modern Radiotherapy, update, 31:(4), 305-308.

13. James RD & Pointon RCS (1985) Gastrointestinal Tract. In: Easson EC and Pointon RCS (eds). The Radiotherapy of Malignant Disease, Heidelberg, Springer Verlag, p 429.

14. James RD, Pointon RCS & Martin S (1985) Local Radiotherapy in the management of Anal Carcinoma. Br J Surg, 72: (4), 282-285.

15. James RD & Schofield PFS (1985) Resection of 'Inoperable' rectal cancer following Radiotherapy. Br J Surg, 72: (4), 279-281.

16. Smith D, Johnson, R, James RD & Thatcher N (1985) Upper abdominal lymphadenopathy as first presentation of relapse identified by ultrasonography, in patients treated for small cell bronchogenic carcinoma. Br J for Dis of the Chest. 79: (2), 141-146.

17. Thatcher N, James RD, Steward WP, Barber PV, Feinmann D, Lawson RAM & Crowther D (1985) Three month's treatment with cyclophosphamide, VP16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer, 56: (6), 1332-1336.

17

18. Thatcher N, Anderson H, James RD, Davenport P & Craig P (1986) Treatment of metastatic melanoma by 24 hour DTIC infusions and hemibody irradiation. Cancer, 57: 2103-2107.

19. James RD, Cummings P, Chang J & Geary C (1987) Alternating half body radiotherapy for lymphoid malignancy. Radiation Research V I, 310. (eds). Fielden, EM et al, Taylor and Frances, London, New York.

20. Johnson RJ, Jenkins JPR, Isherwood I, James RD & Schofield PF (1987) Quantitative magnetic resonance imaging in rectal carcinoma. Br J Radiol, 60: 761-764.

21. Land EJ, Moore JV & James RD (1987) Recent developments in photodynamic therapy in the UK. Int J Radiat Biol, 51: 177-181.

22. Benstead K, James RD & Moore JV (1988) The effect of fractionation of light treatment on necrosis and vascular function of normal skin following photodynamic therapy. Br J Cancer, 58: 528.

23. James RD (1988) Photodynamic therapy in the context of other clinically useful radiations. Br J Radiol, 61: 728, 741.

24. James RD (1988) New Perspectives in Anal and Rectal Cancer: The Move from Radical Surgery. Br J Radiol, 61: 728, 756.

25. James RD (1988) The North West of England Rectal Cancer Trial. Recent results of cancer research, V 110. 104-110, (eds) Springer Verlag, Berlin, Heidelberg.

26. James RD, Williams P, Jones A, Nelis P, Farrow N, Lukka H & Pye DW (1988) Determination of human skin pain threshold using 27 MHz radiofrequency heating. Br J Radiol, 61: 344-346.

27. Moore JV, Benstead K & James RD (1988) Comparative effects of laser hyperthermia and photodynamic therapy (PDT) on the skin and its vasculature. Int J Radiat Biol, 13: 1001.

28. James RD, Notley HM, McDonagh C & Williams PC (1989) 100 KHz Interstitial hyperthermia and immediate high dose rate (Microselectron) Brachytherapy. 10th ESHO Conference Proceedings (publication).

29. James RD, Notley HM, Schofield PF & Williams PC (1989) Modifications of the Papillon technique designed to protect staff. Proceedings of Tripartite Meeting.

30. James RD & Schofield PR (1989) The value of radiotherapy for rectal cancer (ed). Mortensen, M. Baillieres, London. Clin Gastroenterol 3/3: (647-669).

31. Jones DD, Zacovdic J, James RD, Moore M & Schofield PF (1989) Local recurrence after pre-operative radiotherapy and surgery in rectal cancer. Br Surg, 75: 1244.

32. Jones DS, Zacovdic J, James RD, Haboubi N, Moore M & Schofield PF (1989) Predicting local recurrence of carcinoma of the rectum after pre-operative radiotherapy and surgery. Br J Surg. 76: 1172-1175.

33. West CML, Davidson SE, Hunter RD, James RD, Schofield PF, Moore JV & Hendry JH (1989) Surviving fraction at 2 Gy for colony-forming cells in primary cultures of human cervical and colorectal carcinomas. Proceedings of 3rd International Conference on Dose, Time and Fractionation in Radiation Oncology in Prediction of Response in Radiation Therapy: The Physical and Biological Basis pp 86-95.

34. Gray R, James RD & Norman T (1990) "AXIS" A new type of cancer cancer. Clinical Oncology, 2: (3), 125-129.

18

35. James RD & Gray R (1991) The North West of England Colorectal Cancer Trial and the United Kingdom "AXIS" Trial. Non-Surgical. 87: 18-20.

36. James RD, Haboubi N, Salhab N et al (1991) Prognostic factors in colorectal carcinoma treated by pre-operative radiotherapy and immediate surgery. Dis Colon Rectum, 34: 546.

37. West CML, Davidson SE, Pool C, James RD & Schofield PF (1991) Lack of a relationship between colony-forming efficiency and surviving fraction at 2 Gy. Radiat. Res. 126: (2), 260-263.

38. Pettengell R, Gurney H, Radford JA, Deakin DP, James RD, Wilkinson PM, Kane K, Bentley J & Crowther D (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood, 80: 1430-1436.

39. Jones DJ & James RD (1992) ABC of Colorectal Diseases: Anal Cancer (Eds: Jones DJ and Irving MH). pp 65-67.

40. Jones DJ & James RD (1992) ABC of Colorectal Diseases: Anal Cancer. BMJ, 305: 169-71.

41. James RD, Wilkinson PM, Belli F, Welch RS & Cowan RA. (1992) Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta. Haematol. 87: Suppl 1: 12-15.

42. Welch RS, James RD, Wilkinson PM, Belli F, & Cowan RA (1993) Recombinant human erythropoietin and platinum - based chemotherapy in metastatic ovarian cancer. Proc ASCO 12: 254.

43. Wilson MS, West CML, Wilson GD, Roberts SA, James RD & Schofield PF (1993) An assessment of the reliability and reproducibility of measurement of potential doubling times (T

pot)

in human colorectal cancers. Br J Cancer. 67: 754-759.

44. Wilson MS, West CML, Wilson GD, Roberts SA, James RD & Schofield PF (1993) Intra-tumoral heterogeneity of tumour potential doubling times (T

pot) in colorectal cancer. Br J Cancer,

68: (3): 501-6.

45. Wilson MS, Anderson E, Bell JC, Pearson JM, Haboubi NY, James RD. & Schofield PF. (1994) Immunocytochemical estimation of proliferation in human colorectal adenocarcinomas: a comparative study. Surgical Oncology 3: 263-273.

46. Radford JA, Whelan JS, Rohatiner AZS, Deakin D, Harris M, Stansfeld AG, Swindell R, Wilkinson PM, James RD, Lister TA & Crowther D (1994) Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: Results of treatment in 184 patients. Annals of Oncology 5: 147-151.

47. Wilson MS, Anderson E, Bell JC, Pearson JM, Haboubi NY, James RD & Schofield PF.(1994) An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas. Surgical Oncology, 3: (5), 263-273.

48. Marsh PJ, James RD & Schofield PF (1994) Adjuvant Preoperative radiotherapy for locally advanced rectal carcinoma: results of a prospective, randomized trial. Dis. Colon Rectum. 37: No.12, 1205-1214.

49. Welch RS, James RD, Wilkinson PM, Belli F & Cowan RA (1994) Recombinant human

erythropoietin (Epoietin Alfa; Cilag) and platinum - based chemotherapy in advanced ovarian cancer. Annals of Oncology 5: suppl 8, 94.

19

50. Stenning SP & James RD, Axis Steering Group (1994) The Axis colorectal cancer trial: randomization of over 2000 patients. Br J Surg 81: (11): 1672.

51. Marsh PJ, James RD & Schofield PF. (1995) Definition of local recurrence after surgery for rectal carcinoma? Br J Surg. 82: 465-468.

52. James RD (1995) Adjuvant Radiotherapy, In: Colorectal Cancer. (Ed: Williams) Churchill Livingstone, New York.

53. James RD & Barber J. (1995) Radiation responses and human gut. In: Radiation and Gut (Ed: Hendry, J.) Elsevier, Amsterdam.

54. James RD (1995) General Principles of radiation biology. In: Essential General Surgical Oncology. (Ed: Taylor I) Churchill Livingstone, London.

55. Radford JA, Crowther D, Rohatiner AZS, Ryder WDJ, Gupta RK, Oza A, Deakin DP, Arnott S, Wilkinson PM, James RD, Johnson RJ & Lister TA. (1995) Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChIVPP/EVA, in the initial treatment of Hodgkin's Disease. J Clin Oncol. 13: 9: 2379-2385.

56. Logue JP, Kiltie AE, James RD & Wilkinson PM (1995) Continued infusion (CI) of 5-fluorouracil (5FU) in patients with progressive metastatic colorectal carcinoma following intermittent 5FU based chemotherapy. Proceedings of ASCO, Vol 14: 223.

57. Metzner M, Logue J, Wilkinson PM & James RD (1995) Treatment of relapsed ovarian carcinoma with epirubicin, cis-platinum and 5-fluorouracil (ECF). Proceedings of ASCO, Vol 14: 279.

58. Welch RS, James RD, Wilkinson PM, Belli F & Cowan RA. (1995) Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. The Cancer Journal from Scientific American 1: 4: 261-266.

59 Welch RS, James RD, Wilkinson PM, Belli F & Cowan RA (1995) The efficacy of recombinant human erythropoietin (Epoietin Alfa) in the prevention of anemia in patients with advanced ovarian cancer receiving chemotherapy. Proc 9th International Meeting of Gynaecological Oncology, May 9-12, p 171.

60. Robson H, Anderson E, James RD. & Schofield PF. (1996) Transforming growth factor 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 74: 753-75 8.

61. Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WAF, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP & Taylor I for the Colorectal Cancer Working Party of the United Kingdom Medical Research Council. (1996) Randomized trial assessing the addition of interferon -2a to 5-fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol, 14: 8, 2280-2288.

61a UKCCCR Anal Cancer Working (1996) Epidermoid anal cancer results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-Fluorouracil and mitomycin. The Lancet, 348, 1049-1054

62. Cooper RA, James RD. & Taylor KJ. (1996) Cardiac perforation associated with continuous infusional chemotherapy. Clinical Oncology 8: 404-405.

63. Hill J, Slade A, Schofield P, O'Dwyer S & James RD. (1996) Salvage abdominoperineal resection for anal carcinoma. Int. J. Colorectal Disease. Vol 11: No.3: 133.

20

64. James RD (1997) Where next in the treatment of rectal cancer? Clinical Oncology 9: (3) 144-147.

65. Price P & James RD (1997) Toxicity studies in patients receiving radiotherapy in the Quasar Trial. Clinical Oncology...REFERENCE DELETED.

66. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C & Herait P (1998) Randomized trial of Irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.The Lancet 352: No 9138, 1413-1418.

67. Björk-Eriksson T, West CML, Karlsson E, Slevin NJ, Davidson SE, James RD & Mercke C (1998) The in vitro radiosensitivity of human head and neck cancers. Br J Cancer 77:(12), 2371-2375.

68. Iveson T, Eggleton, Hickish & James RD (1998) Irinotecan given 3 weekly for 5 fluorouracil pretreated advanced colorectal cancer (Proceedings of ASCO, 17, p279a)

69. Botwood M, James RD, Vernon C, Purnell C & Price P (1998) Phase I studies of `Tomudex' (Raltitrexed) with pelvic radiotherapy (RT) for adjuvant treatment in patients (PT) with operable rectal cancer (ORC) & recurrent/inoperable rectal cancer (IRC) Br J Cancer 78: (suppl 2) 29-46.

70. Botwood M, James RD, Vernon C, Purnell C, Price P & Smith M (1998) When pelvic radiotherapy is combined with `Tomudex' a dose reduction may be required to avoid increased toxicity. Annals of Oncology Supp 4 to Vol 9: p38.

71. James RD, Vernon C, Price P & Smith M (1998) A pilot study of `Tomudex' plus radiotherapy in patients with inoperable/recurrent rectal cancer. Annals of Oncology, Supp 4 to Vol 9: p41..

72. West RD, Anderson E, Haboubi NY, James RD & O'Dwyer ST (1998) MLHI expression and survival in colorectal cancer. Assoc of Coloproctology of Great Britain & Ireland, Blackwell Science, 76: 19.

73. James RD (1999) Radiation therapy for colorectal cancer, In: Colorectal Cancer. Eds McCardle CS, Kerr D & Boyle P. Isis Medical Media.

74. Gerard JS & James RD (1999) Cancer of the Anus, In: Oxford Textbook of Oncology (In press, January 1999)

75. James RD (1999) Radiotherapy and rectal cancer, In: Recent Advances in Surgery. Eds: Taylor and Johnson (In press, January 1999).

76 Renehan AG, Hill J, Venham S, Lawrence J, James RD, O'Dwyer ST 1999 Transanal Ultrasound Staging for Anal Cancer International Journal of Colorectal Diseases ?? Refs

77. James RD (1999) First line chemotherapy: new medical evidence from ongoing clinical trials: In: Key Advances in the Effective Management of metastatic colorectal cancer. Eds: Cunningham et al. Radcliffe Medical Press .

78. James R and Seymour MT 1999 First line therapy: new evidence for clinical practice in The

effective management of colorectal cancer ed Cunningham, Allen-Mersh, Miles Aesclapius Medical Press, London

79. James RD on behalf of the AXIS collaborators (1999) Adjuvant intraportal 5FU (PVI) and perioperative radiotherapy (RT) in colorectal cancer (The AXIS study - preliminary results). Proceedings of ASCO, 18, p264a.

21

80. Douillard JY, Cunningham D, Roth AD, Germa JR, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Gruia G, Dembak M, Sibaud D & Rougier P (1999) A randomised phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT) (Proceedings of ASCO , 18, p233a.)

81. James RD, Price P, Smith M (1999) Raltitrexed (`Tomudex') plus radiotherapy is well tolerated and warrants further investigation in patients with advanced inoperable/recurrent rectal cancer. (Proceedings of ASCO, 18, p288a).

82. Maughan TS, James RD, Kerr D, McArdle C, Ledermann J, Seymour M, Johnston C & Stephens RJ on behalf of the British MRC Colorectal Cancer Working Party (1999) Infusion 5FU regimens are more effective than Raltitrexed: First results of a multicentre randomised trial in metastatic colorectal cancer. (Proceedings of ASCO 18 May 1999)

83. Rowe MJ & James RD (1999) Acceptability of intermittent infusion chemotherapy for metastatic colorectal cancer as an out-patient procedure: A pilot study (Proceedings of ASCO 18, p605a)

84. Blanke CD, Cassidy J, Gerhatz H, James RD, et al (1999). A phase II trial of TMTX, 5Fu and LCV in patients with previously treated resectable or metastatic colorecal cancer. Proceedings of ASCO p246a).

85. James RD and Seymour MT, 1999, Chemotherapy for advanced colorectal cancer. In challenges in colorectal cancer: Ed. Schofield J, Blackwell Science, Oxford.

86. James RD, (2000) Radiation Therapy for Colorectal Cancer in Colorectal Cancer. Ed.McArdle C, ISIS Medical Media, Oxford.

87. James RD, AXIS: Intraportal 5FU and Peri-operative radiohterapy in the adjuvant treatment of colorectal cancer - Results of the UKCCCR Trial -British Journal of Cancer me 80 Supplement 2 p 20 -4.11.

89. Ledermann JA, Maughan TS, James RD, Kerr D, McArdle C, Seymour M, Johnston C, Stephens RJ 1999 Preliminary Results of a Multi-Centre Randomised Trial Comparing 3 Chemotherapy regimens (DeGramont, Lokich and Railtitrexed) in Metastatic Colorectal Cancer - British Journal of Cancer -Volume 80 Supplement 2 p20 -410.

90. Van Cutsem E and James R, eds 1999 Colorectal Cancer: New Treatment Expectations with Raltitrexed European Journal of Cancer 35 - supplement 1

91. Douillard JY,,Cunningham D, Roth AD, Germa JR, James RD, K Arasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P 2000 Irinotecan combined with Fluorouracil compared with Fluorouracil alone at first-line treatment for metastatic colorectal cancer: A multi-centre trial. The Lancet 355 (9209): 1041-1047

92. Rowe MJ and James RD (1999) Acceptability of intermittent infusion chemotherapy for metastatic colorectal cancer as an outpatient procedure; A Pilot study. Clinical Oncology 18:2338. May 1999 .

93: James RD, Price P and Valentini V, 1999, Raltitrexed (Tomudex (TM)) concomitant with

radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies European Journal of Cancer 35, S19-22

94: Rowe MJ and James RD (1999) Baxter Healthcare/Guild of Healthcare Pharmacist Intravenous

Therapy Award A feasibility study to compare the possibility of patients receiving outpatient deGramont chemotherapy for metastatic colorectal cancer rather than inpatient deGramont chemotherapy. June 1999.Abstract accepted for poster presentation at the American Society of Health Systems Pharmacist mid year meeting. December 1999.

22

95: Rougier P, Cunningham D, Rother A D , Germa JR, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Gruia G, Alakl M, Sibaud D, Douillard JY. Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: Evidence of survival advantage and quality of life (QoL) improvement in metastatic

colorectal cancer (MCRC) European Cancer Conference (ECCO)Abstract 206 13 9 99 Volume 35 Supplement 4.

96: Price P¹, James RD², Smith M³, ¹ Hammersmith Hospital, Department of Clinical Oncology,

London, ²Christie Hospital, Department of Clinical Oncology, Manchester, ³Zeneca Pharmaceuticals, Alderley Park, United Kingdom. 'Tomudex' (raltitrexed)plus radiotherapy as post operative treatment for patients with rectal cancer: Phase 1 studies. European Cancer Confer ence (ECCO)Abstract 223 13 9 99 Volume 35 Supplement 4.

97: Rowe M, James RD, 1999, A prospective comparison of in-patient versus out-patient

DeGramont therapy: Using quality of life, acceptability and response measures: A pilot study. European Cancer Conference (ECCO) Abstract 227 13 9 99 Volume 35 Supplement 4.

97A Rowe M and James R. 1999 A Prospective Comparison of inpatient versus outpatient

DeGramont therapy using quality of life, acceptability and response measures: A pilot study. European Journal of Cancer 2, 267-275

98: James RD, 1999, Chemo-radiotherapy reduces the need for a permanent colostomy. European

Cancer Conference (ECCO) Abstract 1208 13 9 99 Volume 35 Supplement 4. 99: Roger D James and Matthew T Seymour - Chemotherapy for Advanced Colorectal Cancer - Page 166 in Colorectal Cancer - edited by John H Scholefield, Blackwell Science. 100: James RD, (2000) The Impact of NICE and CHI on cancer and diagnostic radiology services.

Radiography. 6: 71-74 101: Van Cutsem E, and James RD, (1999) Colorectal Cancer: New treatment expectations with Raltitrexed. European Journal of Cancer (35) Supp.1. 102: Hayman CM. and James RD, (2000), Emergency admission for surgery predicts disease progression during adjuvant 5-Fluorouracil (5-FU) - based chemotherapy. Colorectal Disease 2 (1): 31-35 103: Botwood M, James RD, and Price P (2000) Raltitrexed ('Tomudex') and radiotherapy can be combined as post operative treatment for rectal cancer. Annals of Oncology 11 (8) 1023-1028 104: James RD, Vaile M, Burrell A, Jackson A, and Alderson A, (2000).Evidence, guidelines audit

and oncology in NICE, CHI and the NHS reforms. Ed. Miles A, et al Aesculapius Medical Press London.

105: Leonard P, Lederman J, James R, Seymour M 2000 Phase II study of Irinotecan and high dose

infusional 5-fluouracil (5-Fu) and folinic acid for first and second line treatment of advanced colorectal cancer. Annals of Oncology 11(4): 44

106: Maughan T, James R, Kerr D, Lederman J, McArdle C, Seymour M, Johnston C, Stephens R

2000 Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer. Annals of Oncology 11(4):43

107: Haboubi NY, El-Zammer O, O'Dwyer S, James RD 2000 Radiation bowel disease:

pathogenesis and management. Colorectal Disease 2(6) 322-330

23

108: James RD 2000 Is hepatic infusion defunct ? in The Effective Management of Colorectal Cancer eds Cunningham, Haller, Miles Aesclapius Medical Press, London

109: James RD and Seymour 2000 Chemotherapy for advanced colorectal cancer in Challenges in

Colorectal Cancer ed Schofield Blackwell Science Oxford 110: James RD 2000 Radiation Therapy for Colorectal Cancer in Colorectal Cancer eds McArdle ,

Kerr, Boyle Isis Medical Media Oxford 111: James RD, Vaile M, Burrell A, Jackson D and Alderson A 2000 Evidence, guidelines, audit and

Oncology in NICE, CHI and the NHS reforms Aesclapius Medical Press LOndon 112: Cunningham D and James RD 2001 Integrating the oral fluoropyrimidines into the

management of advanced colorectal cancer. European Journal of Cancer 37(7) 826-34 113: Maughan T, James R, Kerr D, Lederman J, Seymour M, Topham C, et al 2001 Continuous vs

Intermittent Chemotherapy for Advanced Colorectal Cancer ASCO Proceedings p 125a 114: Radford J, Rohatiner W, Ryder D, Deakin D, Barbui N, Lucie A, Rossi D, Dunlop R, Cown R,

Wilkinson P, James R et al 2001 ChlVPP/EVA Hybrid Chemotherapy for previously untreated Hodgkins Disease ASCO Proceedings p 281a

115. Cooley R, Jackson A and James R 2001 E-commerce, Location and IT Aspects of Kent Cancer

Centre Network. Information & Communications Technology Law 10 (3) 293-8 116. James R and Miles A , Eds, 2002 Managed Care Networks. Aesclapius Medical Press London 117. Cooley R and James R 2001 Clinical Governance and Accountability in Cancer Networks: data

logging and data attribution. In Managed Care Networks. Aesclapius Medical Press London 118. Yap B, Sheen A, Eaton D, Swindell R, James R, et al 2002, A large single centre cohort of

adjuvant chemotherapy following curative resection of hepatic metastases. Proceedings of ASCO, 21 (2), 138b

119. James RD (2002) Radiotherapy, In: Oxford Handbook of Oncology, Ed: Cassidy. Oxford

University Press 120. Hutchinson G, Renehan AG, Levine E, James R and O'Dwyer ST 2002 Impact of Haemoglobin

level on treatment response in patients with anal carcinoma Colorectal Disease 4 (supp 1) 1 121. Maughan TS, James RD, Kerr DJ et al 2002 Comparison of survival, palliation, and quality of

life with three chemotherapy regimes in metastatic colorectal cancer: a multicentre randomised trial Lancet 359: 1555-63

122. James RD, Botwood N, Vernon CC and Price P 2003 Raltitrexed plus Radiotherapy for the

treatment of unresectable/recurrent rectal cancer: a phase I study. Annals of Oncology 14: 570-3

123. James RD and Marks CM 2002 Managed Cancer Networks and the Medical Profession.

Colonews 10 (2) 1-4 124. James RD 2002 Commentary on Kewell et al, Calman Hine reassessed: a survey of cancer

network development in England, 1999-2000 Journal of Evaluation in Clinical Practice 8(3) 299-303

125. Leonard P, Seymour MT, James R et al 2002 Phase II Study of irinotecan with bolus and high

dose infusional 5-FU and folinic acid (modified De Gramont) for first or second line treatment of

24

advanced or metastatic colorectal cancer British Journal of Cancer 87: 1216-20 126. Rowe M, Valle JW, Swindell R, Fitzsimmons L, James R 2002 New face for a familiar friend:

the deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: a feasibility study. Journal of Oncology and Pharmacology Practice 8: 97-103

127. Abson C, James R and Smith C 2003 An Audit of Bisphosphonate Use in Metastatic Breast

Cancer Submitted for Publication 128. James RD 2003 The second UK Phase III anal cancer trial of chemoradiation and maintenance

therapy (ACT II): Preliminary results on toxicity and outcome. Proceedings of ASCO

Proceedings of ASCO, 22, Abstract 1151, 2003. 129. Tobias J, James R, Buchanan R and Beardmore C Eds. 2003 Governance and Revalidation. A

Guide for Clinical Oncologists. The Royal College of Radiologists. London 130. James RD 2003 Key Advances, Non Hodgkins Lymphoma ? full title Aesclapius Medical Press

London 131. James RD 2003 Key Advances, Ovarian Cancer ? full title Aesclapius Medical Press London 132. James RD 2003 Data Implications of the Kennedy Report in ? full title Aesclapius Medical

Press London 133. James RD 2003 Key Advances,Cancer Care in Palliative Networks? full title Aesclapius

Medical Press London 134. Axis Trial Collaborators 2003 The Axis Trial. British Journal of Surgery ?? Citation 135. James RD 2003 and Meadows HM The second UK Phase III anal cancer trial of

chemoradiation and maintenance therapy (ACT II): Preliminary Results on Toxicity and Outcome Proceedings of ASCO 22 287

136. Porter H, Anwar S, Grieve RJ, Carrington BM, Shatwell W, Khoo V, Price P, James RD,

Saunders MP 2003 Concurrent raltitrexed and radiotherapy for locally advanced rectal carcinoma Proceedings of ASCO 22 346

137. James RD Blanco C and Farina C 2003 Savings in Staff time as a result of switching from an

infusional (De Gramont) to an oral (Capecitabine) 5-Fu regime for patients with advanced colorectal cancer. European Journal of Cancer Supp. 1(5): S83

138. Taylor H, Burcombe R, Hill S, Cadwallader S, 2005 James R ?? Publication Evaluation of the

impact on nursing and pharmacy staff resource and patient waiting time of a switch from iv to oral chemotherapy for patients with non small cell lung cancer

139. Saunders MP, Alderson H, Chittalia A, Hughes S, Swindell R, Scott N & James R ???

Publication Preoperative radiotherapy for operable rectal cancer – should we consider reducing the dose of radiotherapy ?

140. James R Meadows H and Wan S 2005 Act II: The second UK Phase III Anal Cancer Trial.

Clinical Oncology 17 (5) 364-6 141. James R 2005 The development of colorectal cancer services through the implementation of

the National Cancer Plan and the operation of cancer networks. In The effective management of Colorectal Cancer Ed. Cunningham, Topham C, Cassidy J and Miles A Aesculapius Medical Press London

25

142. Taylor H, Burcombe R, Hill S, Cadwallader S, James R 2005 Assessing the impact on staff resource and patient waiting time of a switch from IV to oral chemotherapy: Time and motion model for HTA’s. Proc. National Cancer Research Institute (NCRI) Meeting 222: abs pp 435, 2-5 October 2005

143. Shand L, Taylor H, Burcombe R, James R, Hill S, Cadwallader S 2005 Assessing the impact

on staff resource and patient waiting time of a switch from IV to oral chemotherapy: Time and motion model for HTA’s. Proc.. British Oncology Pharmacy Association (BOPA) Meetuing, abstract presented as poster, October 2005

144. Taylor H, Burcombe R, Hill S, Cadwallader S, James R 2005 Asessing the impact on staff

resource and patient waiting time of a switch from IV to oral chemotherapy: Time and motion model for HTA’s. Proceedings of the International Society for Pharmaco-economic Outcomes Research (ISPOR), 5-7, November 2005

145. Burcombe R, Taylor H, Hill S, Cadwallader S, James R 2006 Evaluation of the impact on nursing and pharmacy staff resource and patient waiting time of a switch from oral to IV chemotherapy – a ‘time and motion’ audit. Proceedings BTOG abs 36

146. Saunders MP, Alderson H, Chittalia A, Hughes A, James RD , Armstrong G, Swindell R,

N.Scott NA 2006 Preoperative radiotherapy for operable rectal cancer – is a lower dose to a reduced volume acceptable? Clinical Oncology ?? details (accepted for publication June 2006)

147. Oatey M, Murphy E, Studdart P, Baker G, Wells A, Burcombe R, James R and Bonnett DE 2006 Image Networks for Radiotherapy Planning in a Devolved Radiotherapy Service: Methodology and Quality Assurance. Radiotherapy and Oncology 81 Supp. 1: 5512

148. Matthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, Clare Topham, Roger

James, Stephen J Gwyther, David B Smith, Stephen Shepherd, Anthony Maraveyas, David R Ferry, Angela M Meade, Lindsay Thompson, Gareth O Griffiths, Mahesh K B Parmar, and Richard J Stephens, for the FOCUS Trial Investigators* and the National Cancer Research Institute Colorectal Clinical Studies Group 2007 Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial The Lancet 370: 143-152

149. James R, Northover J, Wan S, Meadows H, Glynne-Jones R, Jitlal M, Lederman J 2008 Long-

term outcome of the first UKCCCR randomised trial of chemo-radiation for the treatment of epidermoid anal cancer. Annals of Oncology 19 (Supplement 8) viii 166

150. U Nur, B Rachet, MKB Parmar, MR Sydes, N Cooper, C Lepage, JMA Northover, R James,

MP Coleman, on behalf of the AXIS collaborators 2008 No socio-economic inequalities in colorectal cancer survival within a randomised clinical trial. British Journal of Cancer 99, 1923 – 1928

151. R. James, S. Wan, R. Glynne-Jones, D. Sebag-Montefiore, L. Kadalayil, J. Northover, D.

Cunningham, H. Meadows, J. Ledermann, 2009 A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). Journal of Clinical Oncology 27, No. 18S, Part II, 797s

152. R James 2009 Oncology capacity planning tool could help trusts assess costs Clinical

Pharmacist Vol 1 July/August

153. R James, S Barni, L Fisher von Weikerstahl, A Garcia Palomo, V Gebbia, O Hansen, A

Martoni, P Meldgaard, A Welt, N Vaissiere 2009 Improving Chemotherapy Capacity by Switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. European Journal of Cancer 7 (2) 211-212

26

154. John Northover, Rob Glynne-Jones , David Sebag-Montefiore, Roger James, Helen

Meadows, Susan Wan, Mark Jitlal, Jonathan Ledermann 2009 Chemo-radiation for the treatment of epidermoid anal cancer: 13-year follow up of the first randomised UKCCCR Anal Cancer Trial (ACT I) Submitted Lancet Oncology awaiting detailed citation

155. James R 2010 Business intelligence and capacity planning: web-based solutions. British Journal of Hospital Medicine. 71(7): 395-398 (July 2010)

156. Roger D James; Sandro Barni; Ludwig Fischer von Weikersthal; Andrés Garcia Palomo; Vittorio Gebbia; Olfred Hansen; Andrea Martoni; Peter Meldgaard; Anja Welt; Nathalie Vaissière 2010 Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: Tamino, an international time and motion audit European Journal of Oncology Pharmacy, Volume 4, , Issue 3, 14-18.

157.